Aurobindo Pharma subsidiary Acrotech Biopharma has launched Adquey difamilast 1 percent ointment in the United States as a non-steroidal topical treatment for mild-to-moderate atopic dermatitis.
The product enters a U.S. market estimated at approximately 1.3 billion dollars based on IQVIA numbers for the 12 months ending July 2026.
Acrotech has established a dedicated dermatology business unit to support the launch and its long-term ambitions in the sector.